{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031157","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.973021+00:00","generated_at":"2026-05-31T10:09:16.528676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Indaptus Q2 net loss $0.47/sh; cash $7.3M; raises $3M in August offering","bullets":["Net loss per share $0.47 for Q2 2024 vs $0.39 YoY; six-month loss $0.92 vs $0.89.","Cash and equivalents $7.3M at June 30, 2024; raised $3.0M (net ~$2.5M) on August 8 via registered direct offering and private placement.","Phase 1 Decoy20 trial: completed one month of weekly dosing in 3 patients at 3x10^7 dose; single dose at 7x10^7 completed.","Presented Decoy20 data at AACR and ASCO; CSO Michael Newman chaired STING & TLR Summit.","Cash runway expected into Q1 2025 based on current operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031157","json":"https://secwatch.observer/filing/0001493152-24-031157.json","markdown":"https://secwatch.observer/filing/0001493152-24-031157.md","text":"https://secwatch.observer/filing/0001493152-24-031157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/0001493152-24-031157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/form-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:09:16.528676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}